The latest price target for Travere Therapeutics (NASDAQ:TVTX) was reported by Citigroup on April 14, 2026. The analyst firm set a price target for $53.00 expecting TVTX to rise to within 12 months (a possible 30.97% upside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Travere Therapeutics (NASDAQ:TVTX) was provided by Citigroup, and Travere Therapeutics maintained their buy rating.

The last upgrade for Travere Therapeutics Inc happened on October 21, 2024 when Wells Fargo raised their price target to $27. Wells Fargo previously had an equal-weight for Travere Therapeutics Inc.

The last downgrade for Travere Therapeutics Inc happened on March 27, 2024 when Guggenheim changed their price target from N/A to N/A for Travere Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on April 14, 2026 so you should expect the next rating to be made available sometime around April 14, 2027.

While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a maintained with a price target of $48.00 to $53.00. The current price Travere Therapeutics (TVTX) is trading at is $40.47, which is out of the analyst’s predicted range.